RxDoctor Payments Data

Robert Galbut, MD

Pulmonary Disease · Miami Beach, FLNPI 1730295486

Payments from drug & device makers

$1,346in general payments, 2019–2025

Across 69 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$686
  • Verona Pharma, Inc.$161
  • AstraZeneca$119
  • Zimmer Biomet$88
  • Boehringer Ingelheim$67
  • Takeda Pharmaceuticals U.S.A., Inc.$49
  • plus $176 from 6 others

What the payments were for

  • Food & beverage$1,346100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,346 in reported general payments places this provider in the 30th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$156,167
Medicare patients
397
Services billed
1,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter178$129,551
EliquisApixaban100$74,000
Breo ElliptaFluticasone/Vilanterol70$31,499
Spiriva RespimatTiotropium Bromide25$17,454
Spiriva HandihalerTiotropium Bromide21$17,303
JanuviaSitagliptin Phosphate15$13,430
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$13,374
JardianceEmpagliflozin11$12,141
SymbicortBudesonide/Formoterol Fumarate29$9,957
LunestaEszopiclone11$9,613
Incruse ElliptaUmeclidinium Bromide21$7,736
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$7,006
Arnuity ElliptaFluticasone Furoate24$6,718
Atrovent HfaIpratropium Bromide12$6,334
Fluticasone-SalmeterolFluticasone Propion/Salmeterol61$6,144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$686$182,510308 claims
PfizerEliquis$46$74,000100 claims
Boehringer IngelheimSpiriva Respimat, Jardiance$67$29,59536 claims
AstraZenecaBreztri Aerosphere, Symbicort$119$23,33046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →